Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Balversa: metastatic Urothelial carcinoma with FGFR3 stated without a specific alteration, FGFR2 stated without a specific alteration (neoadjuvant) after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:susceptible FGFR3 or FGFR2 genetic alterations, andprogressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.

Broader topic: Urothelial Carcinoma

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
neoadjuvant
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    FGFR3
    alteration
    stated without a specific alteration
    status
    present
  2. gene
    FGFR2
    alteration
    stated without a specific alteration
    status
    present
prior therapy
  1. class
    following at least one line of prior platinum-containing chemotherapy
    status
    required
derivation status
source-attested
derivation note
Scoped from the FDA approved indication for Balversa (erdafitinib) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
source wording
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:susceptible FGFR3 or FGFR2 genetic alterations, andprogressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.

Study evidence for this setting

0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

Source relationships and population-mapping limitations
bindings
    mappings

      Download this complete draft source relationship record →

      Preserved source evidence · Not medical advice